BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Army
Healthtrust
Dow
Cantor Fitzgerald
Fuji
McKesson
Queensland Health
Teva
QuintilesIMS

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,759,350

« Back to Dashboard

Which drugs does patent 8,759,350 protect, and when does it expire?

Patent 8,759,350 protects ABILIFY and is included in three NDAs.

This patent has forty-nine patent family members in thirty-one countries.
Summary for Patent: 8,759,350
Title:Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
Inventor(s): Kikuchi; Tetsuro (Tokushima, JP), Iwamoto; Taro (Princeton, NJ), Hirose; Tsuyoshi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:10/540,577
Patent Claim Types:
see list of patent claims
Composition; Use;

Drugs Protected by US Patent 8,759,350

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Otsuka ABILIFY aripiprazole SOLUTION;ORAL 021713-001 Dec 10, 2004 DISCN Yes No ➤ Subscribe ➤ Subscribe ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET, ORALLY DISINTEGRATING;ORAL 021729-002 Jun 7, 2006 DISCN No No ➤ Subscribe ➤ Subscribe ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET, ORALLY DISINTEGRATING;ORAL 021729-003 Jun 7, 2006 DISCN No No ➤ Subscribe ➤ Subscribe ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-006 Nov 15, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-005 Nov 15, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-001 Nov 15, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-002 Nov 15, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-003 Nov 15, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-004 Nov 15, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,759,350

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2002-379003Dec 27, 2002
PCT Information
PCT FiledDecember 25, 2003PCT Application Number:PCT/JP03/16724
PCT Publication Date:July 22, 2004PCT Publication Number: WO2004/060374

Non-Orange Book US Patents Family Members for Patent 8,759,350

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,387,182 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders ➤ Subscribe
9,694,009 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,759,350

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2008131331 ➤ Subscribe
Russian Federation 2356554 ➤ Subscribe
Russian Federation 2005123808 ➤ Subscribe
Portugal 1575590 ➤ Subscribe
Poland 211975 ➤ Subscribe
Poland 378214 ➤ Subscribe
Peru 09232004 ➤ Subscribe
New Zealand 556779 ➤ Subscribe
New Zealand 540054 ➤ Subscribe
Norway 333291 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Teva
Chubb
Covington
Moodys
US Army
McKinsey
Argus Health
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot